Polymyxin B PCD Pharma Franchise Company

Cafoli Lifecare is a WHO-GMP certified Polymyxin B PCD pharma franchise company offering 8 Polymyxin B formulations across Eye Ointment, Eye/Ear Drops, Injection. Every batch is manufactured in DCGI-approved, WHO-GMP compliant facilities and supplied to franchise partners on a monopoly basis with full promotional backing.

What is Polymyxin B?

Polymyxin B is a polypeptide antibiotic active against Gram-negative bacteria, including Pseudomonas aeruginosa. It is a cationic surfactant that binds the lipopolysaccharide of the outer bacterial membrane, disrupting membrane permeability and causing rapid cell death. It is used topically in ophthalmic and otic preparations — usually combined with agents such as neomycin, bacitracin or a corticosteroid — and, as a reserve agent, by injection against multidrug-resistant Gram-negative infections. Polymyxin B is listed on the WHO Model List of Essential Medicines.

Polymyxin B Range Available for Franchise

Our Polymyxin B portfolio comprises 8 formulations available in the following dosage forms: Eye Ointment, Eye/Ear Drops, Injection. Brand names, compositions, packing and net rates are shared on request with partners holding a valid Drug License. Contact us for the current Polymyxin B price list and stock position.

Therapeutic Applications of Polymyxin B

Ophthalmic and otic polymyxin B preparations are used for bacterial conjunctivitis, blepharitis, keratitis, otitis externa and post-operative eye infection prophylaxis. The injectable form is reserved for serious multidrug-resistant Gram-negative infections in intensive care, where it is used strictly under antimicrobial stewardship because of its nephrotoxicity and neurotoxicity profile. Prescribers include ophthalmologists, ENT specialists, and — for the injection — intensivists and infectious-disease specialists.

Why Polymyxin B is a High-Potential Molecule for Distributors

Polymyxin B occupies two very different commercial positions at once, and that is its strength for a distributor. The topical eye and ear drops are a steady, high-frequency retail line: bacterial conjunctivitis and otitis externa are extremely common, seasonal in the humid months, and treated empirically, so the drops move consistently through chemists. The injection, by contrast, is a last-line reserve antibiotic for carbapenem-resistant Gram-negative infections — a threat that is growing in Indian hospitals — which makes it a low-volume, high-value institutional product. One molecule therefore lets a partner serve both a retail eye-care panel and a hospital ICU account.

Why Choose Cafoli Lifecare for Your Polymyxin B Franchise

Cafoli Lifecare works with over 1000+ franchise partners across India. Partners receive monopoly rights for their district or territory, WHO-GMP certified and DCGI-approved products, complete promotional inputs (visual aids, MR bags, samples, prescription pads, gifts), transparent net rates, and dependable dispatch. Our documentation and stock support are built for distributors who want to scale without operational friction.

References

1. PubChem — Polymyxin B compound record (NIH / NCBI)
2. WHO Model List of Essential Medicines
3. PubMed — clinical literature on Polymyxin B